Asuragen to Present at 2016 Association for Molecular Pathology Annual Meeting

Nine Posters and Two Corporate Workshops Present Novel Scientific and Clinical Breakthroughs

AUSTIN, Texas – November 8, 2016 – Asuragen, Inc., a global molecular diagnostics company, will be presenting extensive new scientific and clinical studies at the upcoming Association for Molecular Pathology (AMP) annual meeting, November 10 – 12, 2016 in Charlotte, NC. The presentations by Asuragen scientists and collaborators will cover a broad range of topics, from their latest technology discoveries to advances in genetic disease testing, oncology disease monitoring and NGS profiling of solid and liquid biopsies.

“Our company is focused on delivering innovative molecular solutions to unmet clinical needs in oncology and genetics. The AMP annual meeting provides us with the forum to share our many exciting and groundbreaking clinical and scientific advances from the past 12 months and to continue to demonstrate our commitment to being a leader in oncology and genetics,” said Matthew McManus, M.D., Ph.D., Asuragen’s President and CEO.

At the 2016 AMP annual meeting, Asuragen will host two corporate workshops – one on the newly FDA-cleared BCR-ABL monitoring assay for chronic myeloid leukemia (CML) and a second focused on the performance characteristics and usability of the recently launched QuantideX® NGS RNA Lung Cancer Kit (RUO). In addition, nine scientific posters will highlight recent scientific and clinical findings.

The first workshop will feature presentations by Christopher D. Watt, M.D., Ph.D., Associate Director, Molecular Pathology Laboratory, University of Pennsylvania, Perlman School of Medicine, and Bernard Andruss, Ph.D., Vice President of Diagnostic Development at Asuragen. They will focus on the QuantideX® qPCR BCR-ABL IS Kit and will cover topics ranging from analytical validation data and real-world workflow experience to the clinical implications of using a BCR-ABL minimal residual disease monitoring kit with unprecedented sensitivity (MR4.7) in Chronic Myeloid Leukemia (CML).

In the second workshop, Léon C. van Kempen, Ph.D., Chief Operating Officer & Scientific Director, Dubrovsky Molecular Pathology Centre, Jewish General Hospital, and Gary Latham, Ph.D. Vice President, Research & Technology Development, Asuragen, will present on a routine laboratory’s experience evaluating the QuantideX® NGS RNA Lung Cancer Kit (RUO), analytical sensitivity data, information from a multi-site evaluation and how the integrated, Sample-Aware™ bioinformatics software improves results quality and minimizes sample failures.

Asuragen’s products and technologies are also being featured in nine scientific posters across multiple topics. The breadth of this scientific output from Asuragen reflects the company’s drive to deliver innovative clinical and research solutions that address many current challenges in genetics and oncology. The posters being presented at the conference are:

Poster Session: Friday, November 11 from 2:30 – 3:30 PM

  • BCR-ABL1 Molecular Responses at 12-18 Months Predict Long-Term Event-Free Survival In Patients With Tyrosine Kinase Inhibitor (TKI)-treated Chronic Myelogenous Leukemia (CML): Hematopathology H54: Garrett Eickelberg, OSHU
  • A Novel RT-ddPCR Assay Enables Sensitive and Accurate Quantification of MET Exon 14 Skipping Lung Adenocarcinomas: Solid Tumors S86: Michael Dodge, Ph.D., Asuragen

Poster Session: Saturday, November 12 from 9:45 – 10:45 AM

  • A Streamlined PCR Assay for Rapid and Accurate Genotyping of Poly-T Length Polymorphisms at rs10524523 of the TOMM40 Gene: Genetics G25: Sarah Statt, Ph.D., Asuragen
  • A Putative SNP in the Fragile X Gene Neither Affects PCR-based Genotyping nor is Verified by Sanger Sequencing: Practical Implications for Genome Database Accuracy*: Genetics G57: Homero Rey, Ph.D., Asuragen
  • BCR-ABL1 Monitoring on the IS Using a Clinically and Analytically Validated Multiplex Assay Directly Aligned to the WHO Primary Standards that Unifies Reporting Formats: Hematopathology H31: Justin Brown, Ph.D., Asuragen
  • Independent Evaluation of a Fully-Integrated Next-Generation Sequencing Technology for the Accurate Detection of Oncogenic RNA Fusions and Aberrant Splicing Events in Lung Cancer*: Solid Tumors S19: Richard Blidner, Ph.D., Asuragen
  • A Modular Next-Generation Sequencing Technology that Combines Targeted Enrichment and Bioinformatics Analyses to Reveal RNA Expression and DNA Mutations in Lung Cancer*: Solid Tumors S91: Brian Haynes, Ph.D., Asuragen
  • Multi-Site Evaluation of a Single-Tube Long-Read PCR Assay for the Reliable Detection and Characterization of C9orf72 Hexanucleotide Repeat Expansions*: Technical Topics TT43: EunRan Suh, Ph.D., University of Pennsylvania
  • Performance Assessment of On-Market Liquid Biopsy Nucleic Acid Isolation Technologies: Technical Topics TT71: Jon Kemppainen, Asuragen

*For Research Use Only. Not for use in diagnostic procedures

For more information on Asuragen’s activities at the 2016 AMP annual meeting, visit or stop by booth #1219.

About Asuragen
Asuragen is a global diagnostic products company delivering solutions that build knowledge and understanding of complex clinical questions. Asuragen’s application of its deep scientific heritage and molecular expertise delivers diagnostic products in oncology and genetics that provide the best answers with optimal workflows – so time can be spent delivering actionable insights, rather than searching for them. With innovative approaches to kit development and a broad range of molecular chemistries, Asuragen produces assays that ensure reproducible results. From discovery to regulatory support to global commercialization, we provide a customizable approach that efficiently delivers custom and companion diagnostic products for our partners. We believe people deserve better answers. For more information, visit

Lynne Hohlfeld
Asuragen, Inc.
SVP, Corporate Development and CFO
PH: 512.681.5200


Back To